Selective serotonin reuptake inhibitors (SSRIs) are widely prescribed in the treatment of depression and anxiety, as well as obsessive-compulsive, eating, and impulse-control disorders. Paralleling their widespread use has been an increase in adverse-effect reports not noted during short-term efficacy studies. Significant among these adverse effects is SSRI discontinuation syndrome, which follows the interruption of extended treatment or a reduction in drug dosage and entails somatic and psychological symptoms. These self-limiting symptoms resolve on reintroduction of the drug and cannot be explained as a remanifestation of the original disorder. To facilitate proper diagnosis and avoid unnecessary therapeutic or diagnostic interventions, all physicians who prescribe SSRIs should become familiar with these symptoms. The most appropriate approach to therapy for discontinuation syndrome involves educating patients and reassuring them that this is a reversible condition, reinstating the original SSRI, and further slowing the rate of tapering.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Haddad P. The SSRI discontinuation syndrome.J Psychopharmacol. 1998;2:305–313.
Preskorn SH.Clinical Pharmacology of Selective Serotonin Reuptake Inhibitors. Professional Communications Inc; 1996.
Stahl MMS, Lindquist M, Peterson M, et al. Withdrawal reactions with selective serotonin reuptake inhibitors as reported to the WHO system.Eur J Clin Pharmacol. 1997;53:163–169.
Price JS, Waller PC, Wood SM, Mackay AV. A comparison of post-marketing safety of four selective re-uptake inhibitors including the investigation of symptoms occurring on withdrawal.Br J Clin Pharmacol. 1996;42:757–763.
Black DW, Wesner R, Gabel J. The abrupt discontinuation of fluvoxamine in patients with panic disorder.J Clin Psychiatry. 1993;54:146–149.
Black K, Shea C, Dursun S, Kutcher S. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria.J Psychiatry Neurosci. 2000;25:255–261.
Hindmarch I, Kimber S, Cockle SM. Abrupt and brief discontinuation of antidepressant treatment: effects on cognitive function and psychomotor performance.Int Clin Psychopharmacol. 2000;15:305–318.
Haddad P, Lejoyeux M, Young A. Antidepressant discontinuation reactions.BMJ. 1998;316: 1105–1106.
Lejoyeux M, Ades J. Antidepressant discontinuation: a review of the literature.J Clin Psychiatry. 1997;58(suppl 7):11–16.
Lane RM. Withdrawal symptoms after discontinuation of selective serotonin reuptake inhibitors.J Serotonin Res. 1996;3:75–83.
Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial.Biol Psychiatry. 1998;44:77–87.
Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.J Clin Psychiatry. 1997;58:291–297.
Skaehill PA, Welch EB. SSRI withdrawal syndrome.Consult Pharm. 1997;12:1112–1118.
Benazzi F. Mirtazapine withdrawal symptoms.Can J Psychiatry. 1998;43:525.
Boyd IW. Venlafaxine withdrawal reactions.Med J Aust. 1998;169:91–92.
Diler RS, Tamam L, Avci A. Withdrawal symptoms associated with paroxetine discontinuation in a 9-year old boy.J Clin Psychopharmacol. 2000;20:586–587.
Fava GA, Grandi S. Withdrawal syndromes after paroxetine and sertraline discontinuation.J Clin Psychopharmacol. 1995;15:374–375.
Frost L, Lal S. Shock-like sensations after discontinuation of selective reuptake inhibitors.Am J Psychiatry. 1995;152:180.
Green B. Persistent adverse neurological effects (PANES) following SSRI discontinuation. Psychiatry On-line, 2000. Available at: http://www.priory.com/psych/panes.htm. Accessed November 2001.
Koopowitz LF, Berk M. Paroxetine induced withdrawal effects.Hum Psychopharmacol. 1995; 10:147–148.
Lauber C. Nefazodone withdrawal symptoms.Can J Psychiatry. 1999;44:285–286.
Louie AK, Lannon RA, Ajari LJ. Withdrawal reactions after sertraline discontinuation.Am J Psychiatry. 1994;151:450–451.
Stoukides JA, Stoukides CA. Extrapyramidal symptoms upon discontinuation of fluoxetine.Am J Psychiatry. 1991;148:1263.
Szabadi E. Fluvoxamine withdrawal syndrome.Br J Psychiatry. 1992;160:283–284.
Rosenstock HA. Sertraline withdrawal in 2 brothers: a case report.Int Clin Psychopharmacol. 1996;11:58–59.
Coupland N, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal.J Clin Psychopharmacol. 1996;16:356–362.
Michelson D, Fava M, Amsterdam J, et al. Interruption of selective serotonin reuptake inhibitor treatment.Br J Psychiatry. 2000;176:363–368.
Olver JS, Burrows GD, Norman TR. Discontinuation syndromes with selective serotonin reuptake inhibitors. Are there clinically relevant differences?CNS Drugs. 1999;12:171–177.
Mann AM, MacPherson AS. Clinical experience with imipramine in the treatment of depression.CMAJ. 1959;4:38–47.
Cooper GL. The safety of fluoxetine: an update.Br J Psychiatry. 1988;153(suppl 3):77–86.
Bryois C, Rubin C, Voirol P, Kosel M, Baumann P. Withdrawal symptoms after discontinuation of a citalopram treatment: a prospective study.Eur Neuropsychopharmacol. 1997;7(suppl 2):S142.
Dilsaver SC, Greden JF, Snider RM. Antidepressant withdrawal syndromes: phenomenology and physiopathology.Int Clin Psychopharmacol. 1987;2:11–19.
Schatzberg AF, Haddad P, Kaplan EM, et al. Serotonin reuptake inhibitor discontinuation syndrome: a hypothetical definition.J Clin Psychiatry. 1997;58(suppl 7):5–10.
Goldstein DJ. Effects of third trimester fluoxetine exposure on the newborn.J Clin Psychopharmacol. 1995;15:417–420.
Kent LSW, Laidlaw JDD. Suspected congenital sertraline dependence.Br J Psychiatry. 1995;167: 412–413.
Spencer MJ. Fluoxetine hydrochloride toxicity in neonates.Pediatrics. 1993;92:721–722.
Schatzberg AF, Haddad P, Kaplan EM, et al. Possible biological mechanisms of serotonin reuptake inhibitor discontinuation syndrome.J Clin Psychiatry. 1997;58(suppl 7):23–27.
Rosenbaum JF, Zajecka J. Clinical management of antidepressant discontinuation.J Clin Psychiatry. 1997;58(suppl 7):37–40.
Kaplan EM. Antidepressant noncompliance as a factor in the discontinuation symptoms.J Clin Psychiatry. 1997;58(suppl 7):31–36.
Young AH, Currie A. Physician knowledge of antidepressant withdrawal effects: a survey.J Clin Psychiatry. 1997;58(suppl 7):28–30.
Debattista C, Schatzberg AF. Physical symptoms associated with paroxetine withdrawal.Am J Psychiatry. 1995;152:1234–1235.
Raby WN. Treatment of venlafaxine discontinuation symptoms with ondansetron.J Clin Psychiatry. 1998;59:621–622.
About this article
Cite this article
Tamam, L., Ozpoyraz, N. Selective serotonin reuptake inhibitor discontinuation syndrome: A review. Adv Therapy 19, 17–26 (2002). https://doi.org/10.1007/BF02850015
- selective serotonin reuptake inhibitors
- discontinuation syndrome
- adverse effects